Clinical trials: Dual Antiplatelet Therapy
Intracranial Arteriosclerosis, Ischemic Stroke
Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke
In non-acute symptomatic ischemic stroke, the decision-making of medical treatment plus intracranial stenting has been more and more popular, especially in patients with intracranial large severe stenosis or occlusive artery.
- Conditions
- Intracranial Arteriosclerosis, Ischemic Stroke, Intracranial Arterial Diseases, Arterial Occlusive Diseases
- Trial name
- INSIS (NCT05063630)
- Testing
- Medical treatment plus intracranial stenting, Medical treatment alone
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Can Tho Stroke International Services Hospital
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
Coronary Artery Disease
Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
The study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus steeply discontinued clopidogrel plus aspirin in preventing clinical MACE events.Our subject is beyond a 12-month period patients…
- Trial name
- EASTS (NCT01233167)
- Testing
- clopidogrel
- Volunteers
- 5,232 people
- Sponsor
- Sir Run Run Shaw Hospital
Aortic Valve Stenosis, Stroke
Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI
The purpose of this study is to determine the incidence of major vascular events (ischemic or haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral anticoagulation or dual antiplatelet therapy)…
- Trial name
- AUREA (NCT01642134)
- Testing
- aspirin+clopidogrel (Duoplavin)
- Where
- 4 sites in Spain
- Volunteers
- 124 people
- Sponsor
- Andres Iñiguez Romo, MD, PhD
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Dental Diseases, Antiplatelet Agents
Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.
This is a prospective randomized open-label blinded endpoint (PROBE) The study will be conducted in Maharaj Nakorn Chiang Mai hospital.
- Conditions
- Dental Diseases, Antiplatelet Agents, Antiplatelet Drugs
- Trial name
- NCT03103685
- Testing
- Clopidogrel
- Volunteers
- 428 people
- Sponsor
- Chiang Mai University
Coronary Artery Disease
Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
The DECREASE-PCI trial is a prospective, randomized, placebo controlled, double-blind, phase 4 study to evaluate efficacy and safety of triple anti-platelet therapy compared with dual antiplatelet therapy in patients treated with…
- Trial name
- NCT01346865
- Testing
- Cilostazol
- Where
- 12 sites in South Korea
- Volunteers
- 402 people
- Sponsor
- Seung-Jung Park
Acute Coronary Syndrome
Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes
Phase-3, randomized, multicenter, parallel-group study with blind evaluation of endpoints and intention-to-treat analysis. The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the…
- Trial name
- NEOMINDSET (NCT04360720)
- Testing
- Antiplatelet Monotherapy
- Where
- 50 sites in Brazil
- Volunteers
- 3,410 people
- Sponsor
- Hospital Israelita Albert Einstein
Restenosis
Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel
The ITALIC PLUS Trial was designed with the objective of extending to other countries the enrollment of patients into the ITALIC trial initially conducted in France, in order to achieve statistical significance by pooling the…
- Trial name
- ITALICplus (NCT01476020)
- Where
- France
- Volunteers
- 1,240 people
- Sponsor
- Gilard, Martine
Coronary Heart Disease
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCS
Six months of aspirin plus clopidogrel remains the recommended antiplatelet regimen after percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS), with the more potent P2Y₁₂ inhibitors reserved for the acute…
- Trial name
- NCT07622056
- Testing
- Aspirin 100 mg + clopidogrel (300 mg load → 75 mg daily) ×6 months, then aspirin monotherapy, Aspirin 100 mg + ticagrelor (90 mg load → 45 mg twice daily) ×6 months, then aspirin monotherapy, Ticagrelor (90 mg load → 45 mg twice daily) monotherapy; aspirin stopped at day 2 after randomisation; continued indefinitely
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Stroke, Thrombolysis
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and…
- Conditions
- Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
- Trial name
- NCT07299994
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 462 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Coronary Artery Disease, Depression
Antiplatelet Therapies in Patients With Depression and Coronary Disease
Depression after an acute coronary syndrome (ACS) but also at any time after CAD diagnosis, is highly associated with death, and it predicts mortality more than any other risk factor, comorbidity or follow-up events, suggesting…
- Trial name
- ENHANCE (NCT05821062)
- Testing
- standard Aspirin (ASA) + clopidogrel (CLP) therapy, standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy, standard ASA therapy
- Where
- 2 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Centro Cardiologico Monzino
Coronary Artery Disease
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
Because there is limited data about long-term efficacy and safety about short-term use of cilostazol adding to dual antiplatelet therapy in patients with long or multivessel coronary artery disease after 2nd generation DES…
- Trial name
- ABCD (NCT01192724)
- Testing
- Cilostazol, Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 630 people
- Sponsor
- Yonsei University
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Dual Antiplatelet Therapy, Acute Coronary Syndrome
De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
High bleeding risk (HBR) patients, comprising up to 50% of those presenting with acute coronary syndrome (ACS), are a high-risk group that is increasing in size due to an aging population.
- Conditions
- Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- DESC-HBR (NCT05903976)
- Testing
- P2Y12 inhibitor de-escalation
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Acute Coronary Syndrome
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
A prospective, randomised, open label study of 3 clinically licensed treatments for ACS to assess the effects of these treatments on blood tests of endogenous fibrinolysis.
- Trial name
- VaLiDate-R (NCT03775746)
- Testing
- Clopidogrel 75Mg Tablet, Rivaroxaban 2.5Mg Tablet, Ticagrelor 90Mg Tablet
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- East and North Hertfordshire NHS Trust
Restenosis
The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel
Background Drug-eluting stents (DES) have been extremely successful in reducing restenosis and the need for repeat revascularization procedures in patients who undergo PCI.
- Trial name
- ITALIC (NCT00780156)
- Where
- France
- Volunteers
- 1,235 people
- Sponsor
- French Cardiology Society
Noncardioembolic Cerebral Infarction
Cilostazol Stroke Prevention Study for Antiplatelet Combination
To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in…
- Trial name
- CSPS・com (NCT01995370)
- Testing
- aspirin, clopidogrel, cilostazol
- Where
- Japan
- Volunteers
- 1,884 people
- Sponsor
- Japan Cardiovascular Research Foundation
Non-ST Segment Elevation Myocardial Infarction
Anfibatide Phase Ib-IIa Clinical Trial
Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients
- Trial name
- NCT01585259
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lee's Pharmaceutical Limited
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute